We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
GENVOYA (Gilead Sciences Pty Ltd)
Product name
GENVOYA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
221 working days (255)
Active ingredients
tenofovir alafenamide fumarate; emtricitabine; elvitegravir; cobicistat
Registration type
EOI
Indication
GENVOYA is now also indicated for the treatment of HIV-1 infection in paediatric patients weighing at least 25kg.